January 4, 2014 Operationalizing Hippocampal Volume as an Enrichment Biomarker for Amnestic Mild Cognitive Impairment Trials: Effect of Algorithm, Test-Retest Variability, and Cut Point on Trial Cost, Duration, and Sample Size
May 30, 2013 Identifying Combinatorial Biomarkers by Association Rule Mining in the CAMD Alzheimer’s Database
March 2, 2013 Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing Consortium
March 1, 2013 Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium
May 15, 2012 Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities
April 1, 2012 House Energy and Commerce Committee Hearing C-Path’s work was positively acknowledged by Dr. Janet Woodcock during the April 18 House Energy and Commerce Committee Hear
January 24, 2012 European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical Trials Based on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the
